- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07688642
Circulatory Exercise After Total Knee Replacement
Boosting Venous Return After Knee Replacement: Effects of a Novel Circulatory Exercise on Early Postoperative Inflammation - A Randomized Controlled Trial
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Adults ≥ 18 years undergoing elective unilateral primary TKR for osteoarthritis.
- Able to provide informed consent.
- Able to perform the exercise (cognitively and physically) prior to discharge.
Exclusion Criteria:
- Preexisting peripheral vascular disease with severe ischemia or venous insufficiency that limits exercise.
- Contraindication to early active movement per surgeon (e.g., complex surgical fixation limiting motion if present).
- Severe neurological or cognitive impairment preventing instruction adherence.
- Inability to comply with follow-up.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: standard postoperative TKR rehabilitation (hospital protocol)
|
Participants will receive standard postoperative total knee replacement rehabilitation according to the local hospital protocol, including early mobilization, ROM exercises, quadriceps activation, ambulation training, and standard pain/edema management as clinically indicated.
|
|
Experimental: Circulatory Exercise Protocol (in addition to standard rehab)
|
Participants will receive standard postoperative rehabilitation plus a circulatory exercise protocol including supine leg elevation with ankle pump and knee extension, and seated knee extension with alternating ankle dorsiflexion.
The exercise will be performed at approximately 15 cycles/minute, 10 sets of 1 minute, 60 seconds rest between sets, twice daily for 14 postoperative days.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Difference in postoperative lower-limb edema between the operated and contralateral limbs measured by standardized limb circumference (cm)
Prazo: Baseline/preoperative to postoperative day 14
|
Lower-limb circumference (cm) will be measured bilaterally at standardized anatomical landmarks: 10 cm above the superior border of the patella, at the mid-patellar level, and 20 cm above the superior border of the patella.
Measurements will be obtained on both the postoperative limb and the contralateral (sound) limb.
Edema will be quantified as the side-to-side difference in circumference and the change from baseline.
|
Baseline/preoperative to postoperative day 14
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Postoperative pain intensity measured by the Numeric Rating Scale (NRS, 0-10) at rest and during activity
Prazo: Baseline/preoperative to postoperative day 14
|
Pain intensity will be assessed using an 11-point Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates the worst imaginable pain.
Scores will be recorded at rest and during activity.
|
Baseline/preoperative to postoperative day 14
|
|
Functional mobility:
Prazo: Baseline/preoperative to postoperative day 14
|
Timed Up and Go (TUG) (go for 3 meter and come back). Record assistance level and gait aids. 3-meter walk test at regular base and fast base. |
Baseline/preoperative to postoperative day 14
|
|
Analgesic consumption
Prazo: Baseline/preoperative to postoperative day 14
|
Opioid consumption: record rescue analgesic use
|
Baseline/preoperative to postoperative day 14
|
|
Quadriceps strength via handheld dynamometry.
Prazo: Baseline/preoperative to postoperative day 14
|
Seated 60 Degrees Knee Flexion Patient position Seated on the edge of the table, with feet not in contact with the ground and knee at 60 degrees of flexion. Contact point Posterior aspect of the ankle attachment, at the hook closest to the achilles tendon. Device orientation Horizontal, linked to the ankle strap at one end and anchored to a fixed surface by the cable strap at the other, posterior to the patient's leg being tested. Position of examiner Adjacent to the patient, in a position to situate the DynaMo and instruct the action. Instruction Pull against the DynaMo as hard as you can. 3, 2, 1 - pull, pull, pull and relax. Attachments Tension links, Carabiners, Ankle strap, Tension strap. |
Baseline/preoperative to postoperative day 14
|
|
Neuromuscular electrical stimulation response
Prazo: Baseline/preoperative to postoperative day 14
|
Neuromuscular electrical stimulation response by chattanoga multi-current electrical stimulation.
|
Baseline/preoperative to postoperative day 14
|
|
Patient satisfaction with postoperative recovery measured by a 5-point Likert Scale
Prazo: postoperative day 14
|
Patient satisfaction with postoperative recovery will be assessed on postoperative day 14 using a 5-point Likert Scale, where 1 = very dissatisfied, 2 = dissatisfied, 3 = neither satisfied nor dissatisfied, 4 = satisfied, and 5 = very satisfied.
|
postoperative day 14
|
|
Serum Interleukin-6 (IL-6)
Prazo: Baseline (pre-operative), 24-48 hours post-operative (peak IL-6 window), Baseline/preoperative to postoperative day 14.
|
Interleukin-6 is a pro-inflammatory cytokine and an early mediator of the surgical stress response. Serum IL-6 will be quantified from peripheral venous blood by ELISA. Higher concentrations indicate a greater systemic inflammatory response; IL-6 peaks at approximately 24-48 hours postoperatively. Unit: pg/mL · Reference: < 7 pg/mL (assay-dependent) |
Baseline (pre-operative), 24-48 hours post-operative (peak IL-6 window), Baseline/preoperative to postoperative day 14.
|
|
Hemostasis or clotting tests
Prazo: Baseline/preoperative to postoperative day 14
|
PT (Prothrombin Time) APTT (Activated Partial Thromboplastin Time) D-dimer Fibrinogen
|
Baseline/preoperative to postoperative day 14
|
|
Serum C-Reactive Protein (CRP)
Prazo: Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.
|
C-reactive protein is a hepatically synthesized acute-phase reactant produced in response to IL-6 signaling. Serum CRP will be measured from peripheral venous blood by immunoturbidimetric assay. Higher concentrations indicate greater systemic inflammation; CRP peaks later than IL-6 (~48-72 hours). Unit: mg/L · Reference: < 10 mg/L (hs-CRP: < 1 low, 1-3 moderate, > 3 high cardiovascular risk) |
Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.
|
|
Serum Interleukin-10 (IL-10)
Prazo: Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.
|
Interleukin-10 is an anti-inflammatory cytokine mediating the compensatory anti-inflammatory response to surgical injury. Serum IL-10 will be quantified from peripheral venous blood by ELISA. Higher concentrations indicate a greater compensatory anti-inflammatory response. Unit: pg/mL · Reference: < 10 pg/mL (often < 5 pg/mL; assay-dependent) |
Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.
|
|
Serum Tumor Necrosis Factor-alpha (TNF-α)
Prazo: Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.
|
Tumor necrosis factor-alpha is a pro-inflammatory cytokine released early in the innate immune response to tissue injury. Serum TNF-α will be quantified from peripheral venous blood by ELISA. Higher concentrations indicate a greater pro-inflammatory response. Unit: pg/mL · Reference: < 8.1 pg/mL (commonly < 15-20 pg/mL; assay-dependent) |
Baseline (preoperative), postoperative 24-48 hours, and postoperative day 14.
|
|
Prothrombin Time (PT)
Prazo: Baseline (preoperative) and postoperative day 14.
|
Prothrombin time assesses the extrinsic and common coagulation pathways. PT will be determined on platelet-poor plasma (peripheral venous blood in 3.2% sodium citrate) by an automated clot-based method using a thromboplastin reagent. A prolonged PT indicates impaired extrinsic/common-pathway function. Unit: seconds · Reference: 11-13.5 seconds (INR 0.8-1.1) |
Baseline (preoperative) and postoperative day 14.
|
|
Activated Partial Thromboplastin Time (APTT)
Prazo: Baseline (preoperative) and postoperative day 14.
|
Activated partial thromboplastin time assesses the intrinsic and common coagulation pathways. APTT will be determined on citrated platelet-poor plasma by an automated clot-based method. A prolonged APTT indicates impaired intrinsic/common-pathway function. Unit: seconds · Reference: 25-35 seconds |
Baseline (preoperative) and postoperative day 14.
|
|
D-dimer
Prazo: Frame: Baseline (preoperative) and postoperative day 14.
|
D-dimer is a fibrin degradation product reflecting activation of coagulation and fibrinolysis. D-dimer will be measured on citrated plasma by a latex-enhanced immunoturbidimetric assay. Elevated concentrations indicate increased fibrin turnover (hypercoagulable/prothrombotic state or venous thromboembolism). Unit: µg/mL FEU · Reference: < 0.50 µg/mL FEU (< 500 ng/mL FEU) |
Frame: Baseline (preoperative) and postoperative day 14.
|
|
Fibrinogen
Prazo: Baseline (preoperative) and postoperative day 14.
|
Fibrinogen (coagulation factor I) is the soluble precursor of fibrin and an acute-phase reactant. Plasma fibrinogen will be measured on citrated plasma by the Clauss clot-based method. Elevated concentrations reflect an acute-phase/inflammatory response; low concentrations may reflect consumption or dilution and a bleeding tendency. Unit: mg/dL · Reference: 200-400 mg/dL (2-4 g/L) |
Baseline (preoperative) and postoperative day 14.
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Publicações Gerais
- Huang ZY, Huang Q, Wang LY, Lei YT, Xu H, Shen B, Pei FX. Normal trajectory of Interleukin-6 and C-reactive protein in the perioperative period of total knee arthroplasty under an enhanced recovery after surgery scenario. BMC Musculoskelet Disord. 2020 Apr 21;21(1):264. doi: 10.1186/s12891-020-03283-5.
- Si HB, Yang TM, Zeng Y, Zhou ZK, Pei FX, Lu YR, Cheng JQ, Shen B. Correlations between inflammatory cytokines, muscle damage markers and acute postoperative pain following primary total knee arthroplasty. BMC Musculoskelet Disord. 2017 Jun 17;18(1):265. doi: 10.1186/s12891-017-1597-y.
- Windisch C, Kolb W, Kolb K, Grutzner P, Venbrocks R, Anders J. Pneumatic compression with foot pumps facilitates early postoperative mobilisation in total knee arthroplasty. Int Orthop. 2011 Jul;35(7):995-1000. doi: 10.1007/s00264-010-1091-8. Epub 2010 Jul 22.
- Li H, Zhang W, Lu Q, Wang J, Zhi Y, Zhang L, Zhou L. Which Frequency of Ankle Pump Exercise Should Be Chosen for the Prophylaxis of Deep Vein Thrombosis? Inquiry. 2022 Jan-Dec;59:469580221105989. doi: 10.1177/00469580221105989.
- Lee B, Yoon D, Yim J. Effects of an Early Exercise Program with Cryotherapy on Range of Motion, Pain, Swelling, and Gait in Patients with Total Knee Arthroplasty: A Randomized Controlled Trial. J Clin Med. 2024 Feb 29;13(5):1420. doi: 10.3390/jcm13051420.
- Carnevale Pellino V, Gatti A, Vandoni M, Patane P, Febbi M, Ballarin S, Cavallo C, Marin L. Pneumatic Compression Combined with Standard Treatment after Total Hip Arthroplasty and Its Effects on Edema of the Operated Limb and on Physical Outcomes: A Pilot Clinical Randomized Controlled Study. J Clin Med. 2023 Jun 20;12(12):4164. doi: 10.3390/jcm12124164.
- Incesoy MA, Demirkiran CB, Kaya HB, Geckalan MA, Tak AY, Elmali N, Yildiz F, Uzer G. Natural course of postoperative C-reactive protein and erythrocyte sedimentation rate in unilateral and simultaneous bilateral total knee arthroplasty. BMC Musculoskelet Disord. 2025 Mar 14;26(1):260. doi: 10.1186/s12891-025-08523-0.
- Londhe SB, Shah RV, Doshi AP, Londhe SS, Subhedar K. CRP (C Reactive Protein) level after total knee replacement in Indian population--- does it follow Anglo-Saxon trend? Arthroplasty. 2020 Aug 27;2(1):24. doi: 10.1186/s42836-020-00043-7.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 04-2026-30083
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .